• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Galderma wins FDA nod for dermal fillers

December 15, 2016 By Sarah Faulkner

Galderma wins FDA nod for dermal fillersGalderma said today that it won FDA approval for 2 of its products to treat nasolabial folds, or “laugh lines”.  The Fort Worth, Texas-based company’s Restylane Refyne and Restylane Defyne are made with XpresHAn technology to manufacture injectable gels with customized hyaluronic acid crosslinking in each product.

The federal watchdog’s approval was based on 2 pivotal phase III trials investigating the gels for safety and efficacy. 171 participants used Restylane Refyne and 162 participants were treated with Restylane Defyne. Study investigators and participants reported an improvement in wrinkle severity after 6 weeks of using either Restylane Refyne or Restylane Defyne and both products demonstrated clinically meaningful improvement in wrinkle severity for up to 12 months.

“Even with current approved options, many of my patients are still looking for different solutions to treat their laugh lines,” clinical investigator Dr. Steven Fagien said in prepared remarks. “These new products are flexible and are designed to meet different patient needs. I am excited to offer these next-generation hyaluronic acid (HA) dermal fillers in my practice.”

After treatment with the injectable gels, the participants reported mild and temporary injection site responses such as redness, swelling and bruising. The company is conducting 3 phase IV clinical trials to evaluate the products’ effects over time.

“Restylane Refyne and Restylane Defyne are the latest FDA-approved advancements in HA dermal fillers and align with Galderma’s mission to help individuals achieve natural-looking results through treatments with a long-standing history of proven safety and efficacy,” VP & general manager of U.S. aesthetic & corrective business Kelly Huang said. “We saw an opportunity to address a common concern for patients who have not yet tried a dermal filler by designing gels that provide natural-looking results. With these new brands, the Restylane family of products now represents the broadest offering of HA dermal fillers in the U.S.”

“Many of my patients are interested to learn about the latest products that can help them achieve natural-looking results, but are oftentimes unsure about starting dermal fillers,” dermatologist Dr. Mitch Goldman added. “The introduction of these next-generation HA dermal fillers with XpresHAn technology has the potential to change my patients’ views on fillers. Restylane Refyne and Restylane Defyne provide options for patients who want to make sure they can achieve natural-looking results, which is a key need my patients express every day.”

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Surgical Tagged With: Galderma

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS